Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.

Stocks | Futures | Watchlist | More
or

Bridgebio Pharma Inc (BBIO)

Bridgebio Pharma Inc (BBIO)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
BridgeBio Pharma Receives FDA Fast Track Designation for Investigational Therapy for the Treatment of Limb-girdle Muscular Dystrophy Type 2i (LGMD2i)

/PRNewswire/ -- BridgeBio Pharma, Inc. (Nasdaq: BBIO),a commercial-stage biopharmaceutical company founded to discover, create, test and deliver meaningful medicines for patients with genetic diseases...

BBIO : 50.10 (-0.67%)
BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

/PRNewswire/ -- BridgeBio Pharma, Inc. (Nasdaq: BBIO), a commercial-stage biopharmaceutical company founded to discover, create, test and deliver meaningful medicines for patients with genetic diseases...

BBIO : 50.10 (-0.67%)
BridgeBio Pharma and LianBio Announce First Patient Treated in Phase 2a Trial of Infigratinib in Patients with Gastric Cancer and Other Advanced Solid Tumors

LianBio, a biotechnology company dedicated to bringing paradigm-shifting medicines to patients in China and other major Asian markets, and BridgeBio Pharma, Inc. (Nasdaq: BBIO) today announced the first...

BBIO : 50.10 (-0.67%)
BridgeBio Pharma, Inc. Appoints Finance and Pharmaceutical Leaders Fred Hassan, Andrea Ellis and Douglas Dachille to its Board of Directors

/PRNewswire/ -- BridgeBio Pharma, Inc. (Nasdaq: BBIO),a commercial-stage biopharmaceutical company founded to discover, create, test and deliver meaningful medicines for patients with genetic diseases...

AIG : 55.95 (-1.89%)
BBIO : 50.10 (-0.67%)
BridgeBio Pharma (BBIO) Reports Q2 Loss, Tops Revenue Estimates

BridgeBio Pharma (BBIO) delivered earnings and revenue surprises of 29.03% and 7.97%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?

BBIO : 50.10 (-0.67%)
BridgeBio Pharma: Q2 Earnings Snapshot

PALO ALTO, Calif. (AP) _ BridgeBio Pharma Inc. (BBIO) on Thursday reported a loss of $96.3 million in its second quarter.

BBIO : 50.10 (-0.67%)
BridgeBio Pharma, Inc. Reports Second Quarter 2021 Financial Results and Business Update

/PRNewswire/ -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (BridgeBio or the Company), a commercial-stage biopharmaceutical company founded to discover, create, test and deliver meaningful medicines for patients...

BBIO : 50.10 (-0.67%)
BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

/PRNewswire/ -- BridgeBio Pharma, Inc. (Nasdaq: BBIO), a commercial-stage biopharmaceutical company founded to discover, create, test and deliver meaningful medicines for patients with genetic diseases...

BBIO : 50.10 (-0.67%)
BridgeBio Announces Clinical Collaboration with Bristol Myers Squibb to Study BBP-398, a Potentially Best-in-class SHP2 Inhibitor, in Combination with OPDIVO® (nivolumab) in Advanced Solid Tumors with KRAS Mutations

/PRNewswire/ -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (BridgeBio),a commercial-stage biopharmaceutical company founded to discover, create, test and deliver meaningful medicines for patients with genetic...

BBIO : 50.10 (-0.67%)
BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

/PRNewswire/ -- BridgeBio Pharma, Inc. (Nasdaq: BBIO), a commercial-stage biopharmaceutical company founded to discover, create, test and deliver meaningful medicines for patients with genetic diseases...

BBIO : 50.10 (-0.67%)

Barchart Exclusives

Live Cattle: The Speedo Situation
Some of the chatter I'm hearing about the live cattle market reminded me of a story. Read more

Barchart Futures Commentary

Barchart Futures is a twice weekly newsletter that features a selection of the latest and best commodities commentary appearing on Barchart.com. Delivered every Wednesday and Friday morning to your inbox.

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar